Your browser doesn't support javascript.
loading
Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated".
Pahalyants, Vartan; Murphy, William S; Klebanov, Nikolai; Lu, Chen; Theodosakis, Nicholas; Klevens, Monina R; Estiri, Hossein; Lilly, Evelyn; Asgari, Maryam; Semenov, Yevgeniy R.
Afiliação
  • Pahalyants V; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Murphy WS; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
  • Klebanov N; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
  • Lu C; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
  • Theodosakis N; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
  • Klevens MR; Massachusetts Department of Public Health, Bureau of Infectious Disease and Laboratory Sciences, Boston, Massachusetts.
  • Estiri H; Laboratory of Computer Science, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Lilly E; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
  • Asgari M; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
  • Semenov YR; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ysemenov@mgh.harvard.edu.
J Am Acad Dermatol ; 87(1): e47-e48, 2022 07.
Article em En | MEDLINE | ID: mdl-35364217
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Reumáticas / Antirreumáticos / Rituximab / Vacinas contra COVID-19 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Reumáticas / Antirreumáticos / Rituximab / Vacinas contra COVID-19 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article